Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Science(2022)10.1126/science.abm3425Source: DataRank Database

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial is a research paper published in Science (2022). On theSindex it has a DataRank of 17.7. It has been cited 1,207 times, with 200 citing works in its 1-hop citation network.

N/A

17.7DataRank · unranked

Scored on demand from live citation data

Open Access1,207 citations · 200 citing works in its network

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 106.31)OA: greenTopics (80)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 6%Citation Network 94%

Base Score Contribution

1.1

From this paper's citation signal

Citation Network Contribution

16.6

From 200 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 200 citers.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
New England Journal of Medicine2022392 citations5 referencesContributes 1.195
Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19
JAMA202262 citations5 referencesContributes 0.829
Tracking immune correlates of protection for emerging SARS-CoV-2 variants
The Lancet Infectious Diseases202337 citations7 referencesContributes 0.520
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
Cancer Cell202199 citations11 referencesContributes 0.419
Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
JAMA Network Open202261 citations11 referencesContributes 0.375

Authors (43)

David C. Montefiori ORCID,Adrian B. McDermott ORCID,Youyi Fong ORCID,David Benkeser ORCID,Weiping Deng ORCID

Live enrichment

PubMed:34812653 PMC:PMC9017870 OpenAlex:https://openalex.org/W3217661335

NCATS NIH HHS

Grant: UL1 TR002384

NIAID NIH HHS

Grant: UM1 AI069412

NIAID NIH HHS

Grant: UM1 AI069476

NIAID NIH HHS

Grant: UM1 AI068635

NIAID NIH HHS

Grant: UM1 AI148575

NIAID NIH HHS

Grant: S10 AI174104

NIH HHS

Grant: S10 OD028685

NIAID NIH HHS

Grant: UM1 AI068614

NIAID NIH HHS

Grant: UM1 AI148684

NIAID NIH HHS

Grant: R37 AI054165

NIAID NIH HHS

Grant: U01 AI068635

National Institutes of Health

Grant: 1S10OD028685-01

High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases Research

National Institutes of Health

Grant: 3UM1AI068635-17S4

CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 3UM1AI148684-03S1

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)

Wellcome Trust

FWCI

106.31

Citation Percentile

1.0%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: cc-by

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9017870

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/9017870

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9017870

publisherhttps://www.science.org/doi/pdf/10.1126/science.abm3425

journalhttps://doi.org/10.1126/science.abm3425

Fields of Study

SARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesAnimal Virus Infections StudiesMedicineBiology0303 health sciences03 medical and health sciences2019-nCoV Vaccine mRNA-1273AdolescentAdultAgedAntibodies, NeutralizingAntibodies, ViralCOVID-19Clinical Trials, Phase III as TopicFemaleHumansImmunogenicity, VaccineMaleMiddle AgedRandomized Controlled Trials as TopicSARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusVaccine EfficacyYoung Adult

MeSH Terms

Immunogenicity, VaccineCOVID-19SARS-CoV-2Vaccine Efficacy2019-nCoV Vaccine mRNA-1273AdolescentAdultAgedAntibodies, ViralFemaleHumansMaleMiddle AgedSensitivity and SpecificityRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicYoung AdultAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

AntibodyImmunologyVaccine efficacyImmune systemVaccine trialVirologyImmunityClinical trialMedicinePopulationBiomarkerImmunizationNeutralizing antibodyRegimenBiologyInternal medicineAdultMaleAdolescentSARS-CoV-2COVID-19Middle AgedAntibodies, ViralAntibodies, NeutralizingSensitivity and SpecificityYoung AdultImmunogenicity, VaccineClinical Trials, Phase III as TopicSpike Glycoprotein, CoronavirusHumansFemaleResearch Articles2019-nCoV Vaccine mRNA-1273AgedRandomized Controlled Trials as Topic

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 2 of Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan

10.6084/m9.figshare.26085193.v1figshare

10.6084/m9.figshare.26085193figshare

Additional file 1 of Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis

10.6084/m9.figshare.20501896.v1figshare

Additional file 1 of Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis

10.6084/m9.figshare.20501896figshare

Additional file 1 of The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

10.6084/m9.figshare.21285737.v1figshare

Additional file 1 of The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

10.6084/m9.figshare.21285737figshare

Additional file 1 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623190.v1figshare

Additional file 1 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623190figshare

Additional file 2 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623193.v1figshare

Additional file 2 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623193figshare

Additional file 3 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623196.v1figshare

Additional file 3 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623196figshare

Additional file 4 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623199figshare

Additional file 4 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623199.v1figshare

Additional file 5 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623202.v1figshare

Additional file 5 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623202figshare

Additional file 6 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623205.v1figshare

Additional file 6 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623205figshare

Additional file 7 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623208.v1figshare

Additional file 7 of Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

10.6084/m9.figshare.22623208figshare